2007 Work Programme
Partnership for Progress - ‘Promoting a constructive dialogue between science and society’
The EPDA achieves its success through combining the strengths and experiences of its partners. It has provided an important forum to work in collaboration with European organisations, both patient and neurological, the European Commission, the World Health Organisation, the World Federation of Neurology, and the pharmaceutical industry. This partnership has enabled the development of research projects into quality of life issues, and conferences for multidisciplinary teams and people with Parkinson's of any age.
The EPDA depends on the support of external organisations and companies for funding.
| Platinum |
Gold |
Silver |
Bronze |
Partnership funding (core funds) |
25,000 €
or more
per year |
Between
15,000
and
25,000 €
per year |
Between
5,000 €
and
15,000 €
per year |
Between
1,000 €
and
5,000 €
per year |
This non-restricted funding is supplied on an annual basis by external organisations and companies to enable the EPDA to maintain the organisation including: Auditors, General Assembly, Management, Board meetings, Administration, Website & Publications |
In addition to providing non-restricted core funding, there are opportunities for companies to partner with the EPDA on individual projects and conferences (as set out below) which are of mutual benefit to all concerned.
Publications for production in 2007 |
Date |
Funding confirmed |
Funding required for completion |
EPDA Plus
http://www.epda.eu.com/epdaPlus
Opportunities to provide editorials and advertising
http://www.epda.eu.com/PDInfo/Publications/EPDA/epdaPlus/editorial_advertisingContactForm.asp
Partners
GlaxoSmithKline, Norgine, Novartis, Orion Pharma, Schwarz Pharma, Solvay Pharmaceuticals |
April, August, December |
9,089 € |
11,365 € |
EPNN Journal
http://epda.eu.com/epnn/epnnJournal
Opportunities to provide editorials and advertising
http://www.epda.eu.com/PDInfo/Publications/EPDA/advertisingRates.asp
Partners
Britannia Pharmaceuticals & GE Healthcare |
April, August, December |
32,100 € |
- |
Projects for completion in 2008 |
Date |
Funding confirmed |
Funding required for completion |
Patient Decision Aid:
Focusing on the importance of communication and agreement between the patient and their physician by working with the member organisations, EPDA medical advisory board members and the pharmaceutical industry to compile a simple guide to aid communication and concordance.
Partners
GlaxoSmithKline, Medtronic Foundation, Novartis, Orion, Solvay Pharmaceuticals
The Cure Parkinson's Trust |
Start Date
July 2006
Launch Date
10 April 2008 |
109,050 € |
22,000 € |
PD Nurse Specialists
The aim of this project is the uniform development of PDNS practice and to establish an international framework for guiding the development of minimal standards and core competencies in specialty-focused nursing practice in partnership with ICN, Working Group on PD and
the EPDA.
Partners
Britannia, Lundbeck, Novartis, Orion Pharma & Solvay Pharmaceuticals |
Start Date
June 2006
Completion Date
December 2008 |
54,373 € |
15,616 € |
Ongoing developments throughout 2007 & 2008 |
Date |
Funding confirmed |
Funding required for completion |
Rewrite Tomorrow
This website seeks to bridge the current patient information gap for Parkinson's management. With the support of our experts, we are gathering and reviewing important information that will enable better management on a daily basis and enhance independence.
Partners
Medtronic Europe |
Start Date
January 2006 |
13,400 € |
ongoing |
Coping Strategies – Tips and Tricks
Available via website and DVD
A new website and DVD are in the process of being developed to share
coping strategies or Tips & Tricks that have been created by people with
PD to assist them in their daily lives. The site will contain coping
strategies on several aspects of living with PD including speech and
swallowing, occupational therapy etc.
The Physiotherapy section has begun and is available on the EPDA website (www.epda.eu.com/pwp/copingStrategies). The site contains short
films and people with PD’s comments. The images address tremor and
wearing off periods and how people address them in their daily lives. The
data collected will identify problems and solutions; enabling the sharing of information
with people with PD, their families and healthcare professionals and inspiring
further research.
Data has been collected from Ireland, Luxembourg, Slovenia, Japan and South
Africa. Additional data will be collected from Italy in 2007.
Partners
Lundbeck, Medtronic, Novartis, Orion Pharma, Schwarz Pharma, Solvay Pharmaceuticals & Teva |
Start Date
April 2005
Completion Date
Ongoing |
15,788 € |
10,000 € |
Conferences and Events taking place in 2007 |
Date |
Funding confirmed |
Funding required for completion |
EPDA 7th Multidisciplinary Conference and General Assembly, Italy
6 - 8 October, Lake Stresa, Italy
The EPDA will be holding their annual 1.50 day conference, prior to their General
Assembly.
For the first time, the EPDA is offering the opportunity for companies to hold
their own symposia alongside the conference.
Partners
F. Hoffmann-La Roche Ltd., GE Healthcare, GlaxoSmithKline, Medtronic Europe, Medtronic Foundation, Solvay Pharmaceuticals |
October |
109,137 € |
0 € |
Eastern European Road Shows
This is a new initiative that is a partnership between Hungary and Sweden.
Partners
GE Healthcare, Solvay Pharmaceuticals |
September |
17,600€ |
0 € |
Miscellaneous 2007 |
Date |
Funding confirmed |
Funding required for completion |
Travel Grants for EPDA Board Members
It is required that the EPDA elected Board participate in:
- 2 Board meetings per year
- 1 Conference and General Assembly
|
Beginning
January to December |
10,000 € |
9,710 € |
Board Members are:
- Stephen Pickard - Interim President - Brussels
- Susanna Lindvall - Vice President - Sweden
- Knut-Johan Onarheim - Member at Large - Norway
- Branko Šmid - Treasurer - Slovenia
- Mariella Graziano - Secretary - Luxembourg
- Tom Isaacs - Young-Onset Representative - United Kingdom
- Mahendra Gonsalkorale - Member
- Lizzie Graham - Secretary General - United Kingdom
The travel and accommodation costs, estimated to be 2,500 € per person per year, is met by the EPDA core funding. Partner
Solvay Pharmaceuticals |
.jpg)
